| Project/Area Number |
23792017
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Ophthalmology
|
|---|
| Research Institution | Kanazawa Medical University |
|---|
Principal Investigator |
|
|---|
| Research Collaborator |
HATTA Toshihisa 金沢医科大学, 医学部, 教授 (20238025)
|
|---|
| Project Period (FY) |
2011 – 2013
|
| Project Status |
Completed (Fiscal Year 2013)
|
| Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2013: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Fiscal Year 2012: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Fiscal Year 2011: ¥2,730,000 (Direct Cost: ¥2,100,000、Indirect Cost: ¥630,000)
|
|---|
| Keywords | 可溶型Flt-1 / HMVEC / RNA結合タンパク質 / レンチウイルス / MHVEC / 選択的3'端プロセシング / 血管形成 |
|---|
| Research Abstract |
Here, we showed the mechanisms for regulating alternative 3'-end processing of soluble Flt-1, a potential antiangiogenic factor. We found that hnRNP D down-regulated soluble Flt-1 expression by binding to the regulatory sequence on intron 13 of Flt-1 pre-mRNA. Furthermore, we carried out the lentiviral mediated transgenesis by in vivo manipulation of spermatogonical stem cell. It was suggested that the method was not effective because lentiviral particle couldn't infect to spermatogonical stem cell. Therefore, we are going to create a transgenic mouse conventionally and show the roles of soluble Flt-1 on angiogenesis of eye in vivo.
|
